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MaMany existing and emerging cancer therapies have a signiﬁcant effect on the cardiovascular health of patients with cancer
and cancer survivors. This paper examines current aspects of interdisciplinary cardio-oncology clinical care delivery and
education in the United States and outlines how these data provide a platform for future development of the ﬁeld. We
present the results of the nationwide survey on cardio-oncology services, practices, and opinions, conducted among
chiefs of cardiology and program directors, which demonstrate ranges of clinical activities and identify signiﬁcant
interest for increased educational opportunities and expert training of cardiovascular physicians in this ﬁeld. The survey
respondents recognized clinical relevance but emphasized lack of national guidelines, lack of funds, and limited
awareness and infrastructure as the main challenges for development and growth of cardio-oncology. We discuss
potential solutions to unmet needs through interdisciplinary collaboration and the active roles of professional societies
and other stakeholders. (J Am Coll Cardiol 2015;65:2739–46) © 2015 by the American College of Cardiology Foundation.E vidence increasingly shows that cancer andheart disease are inextricably linked, whetherthrough common risk factors, coexistence
of both diseases in an aging population, or them the *MedStar Heart and Vascular Institute, MedStar Washington Hospit
spital, Chicago, Illinois; zAbramson Cancer Center, University of Pennsylv
spital and Dana-Farber Cancer Institute, Harvard Medical School, Boston
lorado; {Mayo Clinic and College of Medicine, Rochester, Minnesota; #M
an School of Medicine at the University of Pennsylvania, Philadelphia, Pe
dical School, Boston, Massachusetts; zzRush University Medical Cente
uston, Texas; kkThe Heart Institute, Cincinnati Children’s Hospital Medi
rdiology, Washington, DC; and the ##Duke Clinical Research Institute, D
rolina. The views expressed in this paper by the American College of Cardi
not necessarily reﬂect the views of the Journal or the American College of
L2TR000102-04 (to Dr. Barac). Dr. Barac has received research support fro
d honoraria for lectures from Genentech, Inc.; and consultancy fees fr
ployee of Abbott Diagnostics in July 2015 but was not afﬁliated with
. Freeman has served as a consultant to Gilead; and has served as a sp
sultant to ARIAD Pharmaceuticals and Bristol-Myers Squibb; and as a me
d Bristol-Myers Squibb. Dr. Ky has received research support from Pﬁzer, t
. Mayer has received research support from Pﬁzer, Eisai, and Myriad. Dr. Do
ncer Institute and the University of South Florida. All other authors have
contents of this paper to disclose.
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
nuscript received April 28, 2015; accepted April 30, 2015.deleterious effects of cancer treatments on cardiovas-
cular (CV) health. Despite a growing recognition of
the importance and complexity of these relation-
ships, the vast majority of CV professionals have littleal Center, Washington, DC; yNorthwestern Memorial
ania, Philadelphia, Pennsylvania; xBoston Children’s
, Massachusetts; kNational Jewish Health, Denver,
D Anderson Cancer Center, Houston, Texas; **Per-
nnsylvania; yyDana-Farber Cancer Institute, Harvard
r, Chicago, Illinois; xxBaylor College of Medicine,
cal Center, Cincinnati, Ohio; {{American College of
uke University School of Medicine, Durham, North
ology’s Prevention of Cardiovascular Disease Section
Cardiology. This work was supported in part by NIH/
m the National Institutes of Health; research support
om Cell Therapeutics, Inc. Dr. Murtagh will be an
this company at the time this paper was written.
eaker for Medtronic. Dr. Hermann has served as a
mber of advisory boards for ARIAD Pharmaceuticals
he National Institutes of Health, and PA Cure Health.
uglas has received research grants from the National
reported that they have no relationships relevant to
ntin Fuster.
ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College of
Cardiology
ASCO = American Society of
Clinical Oncology
CV = cardiovascular
NCI = National Cancer Institute
Barac et al. J A C C V O L . 6 5 , N O . 2 5 , 2 0 1 5
Council Clinical Perspectives: Cardio-Oncology J U N E 3 0 , 2 0 1 5 : 2 7 3 9 – 4 6
2740training or exposure to the many new ad-
vances in the ﬁeld of cancer therapeutics and
their possible adverse CV effects. There are
substantial opportunities for CV specialists
to advance partnership with oncologists in
exploring new strategies to preserve and
restore optimal CV health of patients with can-
cer and cancer survivors and for CV scientists
to unravel the links between these disorders.Due to signiﬁcant College-wide interest, the
American College of Cardiology’s (ACC’s) Early Career
section has developed a working group to explore the
potential in developing this new focus on cardio-
oncology, including a potential new member sec-
tion: Cardio-Oncology. In collaboration with ACC
staff, this group has performed an environmental scan
and conducted a nationwide survey of cardiologists
regarding their views on cardio-oncology services,
practices, and opinions to identify patient and pro-
fessional needs in this growing ﬁeld.
The aim of this paper is to summarize the key
current aspects of interdisciplinary cardio-oncology
clinical care delivery and education in the United
States and to outline how these data provide a plat-
form for future development of the ﬁeld. As part of
the ACC’s strategic mission to provide a professional
home for CV specialists, we examine existing in-
terests and expertise, as well as available forums
and opportunities for education and knowledge ex-
change. This paper does not present a comprehensive
review of the considerable clinical or research publi-
cations within cardio-oncology, but rather a snapshot
of the needs and opportunities in patient care,
training, and education in this ﬁeld. We then discuss
potential next steps to advance the ﬁeld and inter-
disciplinary collaboration.
THE ORIGINS OF CARDIO-ONCOLOGY
OR ONCO-CARDIOLOGY
The terms “cardio-oncology” and “onco-cardiology”
have both been used to describe this ﬁeld, encom-
passing a continuum of CV risk stratiﬁcation, pre-
vention, and treatment that spans the timeline from
cancer diagnosis into survivorship (Figure 1) and that
depends on close collaboration across cardiology and
oncology specialties (1–3). The origins of the ﬁeld date
back to the late 1960s, when anthracyclines, potent
new antitumor compounds, were widely introduced
into the therapeutic regimens of many cancers (4–6).
Observations of their dose-dependent cardiotoxic
effects not only led to critical modiﬁcations of
anthracycline-based regimens with cumulative dose
limits (7), but also spurred research directed towardthe understanding, diagnosis, and prevention of car-
diac toxicity. Anthracycline-induced cardiac injury
became a prototype of what later was named type I
cancer therapy–related cardiac dysfunction, char-
acterized by ultrastructural evidence of necrosis,
dose dependence, and largely irreversible effects on
cardiac muscle (8,9). In contrast, type II cancer
therapy–related cardiac dysfunction is associated
with the use of molecularly targeted cancer thera-
peutics, the effects of which are not dose related, do
not have molecular evidence of necrosis, and are
often reversible (8,9).
Since these early clinical and pathological obser-
vations, our knowledge about cardiotoxicity has
seen impressive growth fueled by molecular in-
vestigations of traditional and numerous new cancer
therapeutics (10–12), translational research using
biomarkers and imaging for CV prediction and risk
stratiﬁcation (13–18), clinical trials evaluating the
effects of cardioprotective strategies (19–22), as
well as epidemiologic investigations into the bur-
den of these diseases (23–26). In addition to cardiac
dysfunction and heart failure, the spectrum of
cardiovascular effects related to cancer therapies
(spanning many cancer therapeutics and radiation
treatments) includes, but is not limited to, arrhyth-
mias, valvular heart disease, accelerated atheroscle-
rosis, and pericardial disease. The reader is invited
to in-depth reviews of these broad investigational
areas (27–33).
The growth of research and clinical activities, evi-
denced by an exponential increase in the number
of publications in the ﬁeld (Figure 2), has set the
foundation for a new discipline, aimed not only at
screening, preventing, and treating CV effects of
cancer therapies, but also at forming a partnership in
providing comprehensive CV care for patients with
cancer and cancer survivors (1–3).
EXISTING CARDIO-ONCOLOGY PROGRAMS:
A VANGUARD?
Growing clinical demand has resulted in the emer-
gence of dedicated cardio-oncology programs across
the United States, frequently at tertiary/quaternary
referral centers with both comprehensive cancer
centers and dedicated heart failure programs. The MD
Anderson Cancer Center, Memorial Sloan Kettering
Cancer Center, Vanderbilt-Ingram Cancer Center,
University of Pennsylvania Abramson Cancer Center,
and Dana-Farber Cancer Institute have pioneered
these programs and have set critical groundwork in
the ﬁeld. However, these programs have formed in
isolation, as currently there is no coordinating
FIGURE 1 Continuum of CV Care in Cardio-Oncology
An example of the continuum of cardiovascular (CV) care on a timeline of cancer diagnosis, treatment, and survivorship. Patient A represents a patient
with no existing cardiovascular disease (CVD), and Patient B represents a patient with a pre-existing CV condition. CAD ¼ coronary artery disease;
HF ¼ heart failure.
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2741professional association to guide and bridge their
development. Despite this lack of external recogni-
tion, experience suggests that rapid growth in CV
services occurs once a dedicated service is intro-
duced. In 2000, the Department of Cardiology at
MD Anderson Cancer Center had 4 general cardiolo-
gists managing 1,300 new consults, 3,700 inpatients,
and 3,900 echocardiograms and electrocardiograms
yearly (C. Iliescu, personal communication, December
2014). Since that time, this group has grown into a
comprehensive CV service, including interventional,
electrophysiology, and advanced heart failure ser-
vices, with 2,500 new consults, 8,600 inpatient
follow-up visits, and 75,000 imaging tests andCV procedures in 2014 (17,000 echocardiographic
studies, 55,000 electrocardiograms, 2,000 cardiac
catheterization and electrophysiology procedures,
and 1,000 vascular and nuclear medicine studies)
(C. Iliescu, personal communication, December 2014).
Cardiomyopathy and cardiotoxicity represent 20%
to 30% of the practice, with the remainder comprising
pre-cancer therapy risk stratiﬁcation and manage-
ment, acute coronary syndromes, cardiac dysrhyth-
mias, pericardial disease, and cardiac tumors.
Although these few, highly specialized CV centers
are likely to provide excellent care for this patient
cohort, the vast majority of patients with cancer and
survivors are cared for in community-based practices,
FIGURE 2 PubMed Citations in “Cardio-Oncology”
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2742rather than in academic settings. In such settings,
the volume is expected to be much lower, affording
physicians less experience in managing cardio-
oncology concerns. Indeed, recent reports suggest
that patients with cancer may be undertreated with
regard to their CV risk compared with similar cancer-
free cohorts (34,35). These observations have caused
controversy and point to the need for better under-
standing and attention to the delivery of CV care for
this heterogeneous patient population across diverse
practice settings.
NATIONAL CARDIO-ONCOLOGY SURVEY
To evaluate the current state of cardio-oncology ser-
vices, practices, and opinions within the wider ACC
community, we conducted a nationwide online sur-
vey of 444 adult and pediatric cardiology division
chiefs and CV fellowship program training directors.
The rationale for focusing on division chiefs and
training directors was because of their likely knowl-
edge of existing clinical and educational cardio-
oncology activities, as well as our working group’s
interest in their perception of the needs and potential
barriers for development of cardio-oncology services,
education, and training. Although the choice of this
target population biased our sample in favor of aca-
demic institutions and limited representation of
community awareness and efforts in our results, it
provides an important insight into potential future
opportunities for cardio-oncology knowledge dis-
semination from tertiary CV training centers into the
community. The survey was conducted from May 5,2014, to May 28, 2014, with reminders sent on May
13 and May 20. A total of 106 CV specialists
completed the survey for an overall response rate of
24%. The majority of participants were cardiology
fellowship training directors (44%) or cardiology
division chiefs (25%) working at academic medical
centers (76%). (All results are shown in the Online
Appendix.) More than one-half described their
heart failure program as involving transplant (56%)
and their oncology program as representing a Na-
tional Cancer Institute–designated Comprehensive
Cancer Center (53%).
PERCEIVED IMPORTANCE OF CV CARE IN PATIENTS
WITH CANCER. The majority of respondents (>70%)
felt that CV implications of cancer treatment were
a very important consideration in the continuum
of treatment of patients with cancer, and two-thirds
(65%) thought that access to consultants with
specialized training would provide an advantage in
caring for patients who experience CV complications
from anticancer treatments. In the majority of cen-
ters, the estimated number of CV imaging tests for
oncology patients was between 100 and 500 per year,
with somewhat lower estimated numbers of CV
consults.
CURRENT CARDIO-ONCOLOGY PROGRAMS AND
TRAINING. In 35% of centers, cardio-oncology activ-
ities fall within pre-operative consultation services
managed by general cardiology, whereas 27% of
centers reported having an established, specialized
cardio-oncology service with multiple clinicians. A
total of 16% of respondents reported relying on a
J A C C V O L . 6 5 , N O . 2 5 , 2 0 1 5 Barac et al.
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2743single cardiologist with expertise in the area, and
12% currently offer no cardio-oncology services but
plan to add them within the next year.
PERCEIVED LEVEL OF UNDERSTANDING AMONG
FELLOW SPECIALISTS. A signiﬁcant number of the
participants (39%) did not feel conﬁdent in dealing
with CV care speciﬁc to patients with cancer, and
participants gave themselves an average rating when
asked about their level of understanding of the
effect of holding or stopping anticancer treatment on
cancer outcomes. At the same time, cardiologists gave
their peer oncologists an average rating about theirTABLE 1 Current and Future Opportunities in Advancing CV Care in P
Cardio-Oncology Area Examples of Recent and Cur
Best clinical care practices  The ASCO Survivorship Guidelines
oping a clinical guidance document
toring of cardiac dysfunction in sur
 The SCAI is developing a document
of cardio-oncology patients in the c
laboratory.
 NCCN Guidelines for Survivorship
a new algorithm with recommendat
anthracycline-induced cardiac toxic
 The ASE and the EACVI have pu
documents on multimodality imagin
vascular complications of radiother
during and after cancer therapies (3
Research  The NCI and NHLBI convened a work
Related Cardiotoxicity: Understandi
Knowledge and Developing Future
to establish scientiﬁc priorities rega
related cardiotoxicity.
 NCI’s Cardiotoxicity Working Group
several pilot studies of the utility o
biomarker techniques in cancer clin
personal communication, April 2015
Education  MD Anderson and ICOS organize bia
on CV effects of cancer therapies.
 MD Anderson web-based audiovis
Anderson Practices in Onco-Cardiol
relevant to heart disease in patient
cardiotoxicity (40).
 ICOS holds monthly webinars with
cases and cardio-oncology topics (4
 Cancer and the Heart textbook by M
addresses broad aspects of cardioto
 ACC.15 featured “Cardio-Oncology
half-day session with multidisciplin
 ASCO’s CME modules focus on the
and medical concerns related to CV
Training  Only a few institutions offer adv
oncology. There are no advanced tr
Collaborations of stakeholders  NCI-NHLBI Workshop on cardiotoxic
partnership between different gove
agencies and professional societies
 ASCO and ACC have formed a w
explore opportunities for collaborat
ACC ¼ American College of Cardiology; ASCO ¼ American Society of Clinical Oncology; A
Training Statement; CV ¼ cardiovascular; EACVI ¼ European Association of Cardiovascu
National Cancer Institute; NHLBI ¼ National Heart, Lung, and Blood Institute; SCAI ¼ Sounderstanding of the effect of slow or inadequate
cardiology assessment on the development of CV
complications in oncology patients. More than one-
half (52%) of respondents agreed (vs. 9% who dis-
agreed) that a cardio-oncology service or a dedicated
clinician would improve the care of patients with
cancer.
BARRIERS TO ESTABLISHMENT OR EXPANSION OF
CARDIO-ONCOLOGY SERVICES. Lack of national
guidelines and lack of funding were the most fre-
quently cited barriers to the establishment of a cardio-
oncology service (both cited by 44%), followed byatients With Cancer and Cancer Survivors
rent Activities Possible Future Steps
Advisory Group is devel-
on prevention and moni-
vivors of adult cancers.
on special considerations
ardiac catheterization
, Version 1.2015, include
ions for the treatment of
ity (37).
blished expert consensus
g in evaluation of cardio-
apy (38) and in patients
9).
 Development of additional clinical practice documents
in the areas of diagnosis, CV monitoring, prevention, and
treatment of CV disease in patients with cancer and cancer
survivors. This includes a number of focused, cancer
treatment–related, and survivorship-related cardiotoxicity
guidelines with multidisciplinary group inclusion.
 Quality of care improvement initiatives with broader
implementation of existing databases and development of
new database models adapted for interdisciplinary care.
shop: “Cancer Treatment–
ng the Current State of
Research Priorities” (31)
rding cancer treatment-
is currently funding
f various imaging and
ical trials (L. Minassian,
).
 Enhancement of efforts and funding in all areas including,
but not limited to, outcomes and epidemiology, basic
science, translational science, and clinical trials.
 Critical integration and validation of data, mostly from
single academic institutions, to conﬁrm clinical effective-
ness and inform clinical practice activities with eventual
guideline generation.
nnual conferences focused
ual lecture series on MD
ogy discuss topics
s with cancer and
live discussions of clinical
1).
D Anderson authors
xicity (42).
Intensive,” a dedicated
ary participation.
oncologist’s perspective
toxicity (43,44).
 Further development of educational content for cardiology
providers covering rapidly evolving areas, such as targeted
therapeutics, novel cancer-treatment combination therapy
regimens, prevention, and role of cardiologists in
survivorship programs.
 Further development of tools for knowledge dissemination,
such as CME courses, online tools and applications, work-
shops, and integration with national and international
conferences.
 Collaboration with oncology professional societies in
development and dissemination of educational materials
for oncology providers.
anced training in cardio-
aining standards.
 Development of cardio-oncology–speciﬁc competencies,
training assessment tools, and curricular milestones based
on COCATS recommendations (36). This will include devel-
opment of criteria and standardization of advanced training
(Level II and III training). Successful examples of CV areas
included in COCATS 4 include CV prevention, vascular
medicine, critical care cardiology, and others (36).
ity highlighted the role of
rnment and regulatory
(31).
orking group charged to
ion.
 Further collaborative efforts with cardiology and oncology
professional societies in developing clinical practice stan-
dards and curricula for training programs.
 Advocacy for policies supporting cardio-oncology care
with government agencies and regulatory agencies.
 Advancement of cardio-oncology research initiatives and
funding by government and other sponsors.
SE ¼ American Society of Echocardiography; CME ¼ Continuing Medical Education; COCATS ¼ Core Cardiovascular
lar Imaging; ICOS ¼ International CardiOncology Society; NCCN ¼ National Comprehensive Cancer Network; NCI ¼
ciety of Cardiac Angiography and Interventions.
CENTRAL ILLUSTRATION Overview of the Spectrum of Cardio-Oncology: Bench to Bedside to Community
Barac, A. et al. J Am Coll Cardiol. 2015; 65(25):2739–46.
Partnerships across and within the disciplines of cardiology and oncology in the areas of research (basic, translational, clinical, and population science),
education and clinical training, and guidelines and clinical documents development as a potential solution to unmet needs and advancement in patient care.
CV ¼ cardiovascular.
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2744limited interest (38%), infrastructure (36%), and
educational opportunities (29%). Only 7% felt there
were no barriers. Many programs reported having
no formal training in cardio-oncology (43%), with some
institutions offering exposure during regular clinical ro-
tations (43%) and a small number including lectures in
cardio-oncology as part of the core curriculum (11%).
Importantly, 70%of respondents reported that theywould
be likely to use educational material for their fellows and
staff, if those were available.
More than one-quarter (27%) of respondents (n¼ 29)
offered additional comments to express needed sup-
port in the ﬁeld of cardio-oncology, speciﬁcally the
need for educationalmaterials and dedicatedmeetings
(25%), training and curriculum (22%), clinical rele-
vance and growth (19%), and the development of
guidelines (13%). Two respondents (6%) listed con-
cerns about excessive splitting of the CV specialty into
subspecialties.ROADMAP TO THE NEXT LEVEL
The survey results document a widespread appreci-
ation of the importance of CV concerns in patients
with cancer and a recognized need to improve the
care of these patients through provision of special-
ized services. However, the survey also notes signif-
icant barriers. Plans to develop cardio-oncology must
recognize both the opportunities and the potential
hurdles. The ACC’s recognition of the importance of
this area and dedication to its advancement is mani-
fest by the recent creation of a member section in
cardio-oncology, which is a major step forward.
In planning for this section, the Cardio-Oncology
Working Group considered current and future oppor-
tunities in broad areas of best clinical practices,
research, education, and training (Table 1). The activ-
ities listed represent an arbitrary and narrow sample
that is evolving rapidly (and will be outdated soon)
J A C C V O L . 6 5 , N O . 2 5 , 2 0 1 5 Barac et al.
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2745but aim to give an insight into successful seminal
efforts that now need to be broadened (Central
Illustration). For example, our survey identiﬁed a
need for training in cardio-oncology that currently
exists only at a few comprehensive cancer centers
that possess a critical concentration of expert faculty,
clinical volume, and complexity. Expansion of these
efforts is necessary to meet the growing demand for
trained CV specialists. The establishment of the key
competencies within cardio-oncology and the tools
necessary to assess training and establish progress,
following the Core Cardiovascular Training State-
ment recommendations (36), will be required to allow
further successful growth of the ﬁeld. Similarly,
within broad areas of research and clinical standards
in cardio-oncology, there is a need for critical vali-
dation and integration of the data from single aca-
demic institutions, further development of methods
and standards, and strategic implementation and
dissemination of knowledge.The Cardio-Oncology member section will serve
as a professional home for the growing number of
specialists and allow them to share best practices,
develop educational tools and practice standards,
design training programs, advocate for cardio-
oncology, as well as collaborate with oncology spe-
cialists. It is through these advancements and critical
partnerships within cardiology and across specialties
that a value-based proposition of improved patient
care and outcomes will be fulﬁlled.
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